Project Grant R01HL184552

The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $863,551 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to improve external validity of the RECHARGE trial through a partially randomized patient preference framework.

The RECHARGE program comprises two integrated multicenter randomized trials—RECHARGE:WOMEN and RECHARGE:MINORITIES—that compare percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in women and Black or Hispanic patients with multivessel coronary artery disease. The trials will enroll approximately 1,200 patients across up to 100 sites, with a hierarchical composite primary endpoint of death and time-averaged change in generic quality of life. The funded project addresses a critical feasibility challenge: during RECHARGE's pilot phase, 80 percent of eligible patients declined randomization due to strong treatment preferences. The grant funds integration of a partially randomized patient preference cohort framework to enroll these preference-driven patients in a parallel observational arm within a unified analytic design, thereby enhancing generalizability and evaluating the feasibility of incorporating preference cohorts in cardiovascular randomized controlled trials. This approach has not previously been deployed in coronary revascularization research.

Period of performance runs through May 31, 2031. Work is performed at Weill Medical College's location in New York, New York.